Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320060
Status:
COMPLETED
Last Update Posted:
2006-04-27
First Post:
2006-04-27
Brief Title:
Effect of Pyridorin in Patients With Diabetic Nephropathy
Sponsor:
BioStratum
Organization:
BioStratum
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Multi-Center 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin Pyridoxamine Dihydrochloride in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2006-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin pyridoxamine dihydrochloride 50 mg given orally twice daily in patients with diabetic kidney disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None